Cuvitru Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to growing diagnosis of primary immunodeficiency disorders, expansion of plasma collection networks, improved immunoglobulin purification processes, rising adoption of replacement therapies, increased specialist immunology care.

The growth in the forecast period can be attributed to expansion of home healthcare immunotherapy, rising demand for convenient self-administration options, increasing investment in plasma fractionation capacity, growing focus on personalized dosing regimens, advancement in immunoglobulin formulation technologies. Major trends in the forecast period include increasing use of subcutaneous immunoglobulin therapies, rising preference for home-based infusion treatments, expansion of long-term immunodeficiency management, improved patient-centric delivery methods, enhanced plasma-derived product safety.

The rising prevalence of immunodeficiency diseases is anticipated to drive the growth of the Cuvitru market going forward. Immunodeficiency diseases are a group of conditions in which the immune system does not function effectively, leaving individuals more vulnerable to infections and other health complications. The growing occurrence of immunodeficiency diseases is linked to factors such as improved diagnostic capabilities leading to higher detection rates, environmental influences including pollution and climate change that affect immune health, and an aging population that is more susceptible to immune system decline. Cuvitru plays an important role in the treatment of immunodeficiency diseases by providing subcutaneous immunoglobulin replacement therapy, which helps strengthen immune function and reduce the frequency and severity of infections in patients with primary and secondary immunodeficiencies. For example, in 2023, according to the Immune Deficiency Foundation (IDF), a US-based nonprofit organization, approximately 1,177 patients were reported to be living with primary immunodeficiency, with common variable immune deficiency accounting for 62% of cases. Therefore, the growing prevalence of immunodeficiency diseases is contributing to the expansion of the Cuvitru market.

The expanding aging population is expected to further propel the growth of the Cuvitru market in the coming years. The aging population includes individuals aged 65 years and older who commonly experience age-related physiological changes, including a gradual decline in immune system function. The increase in the geriatric population is driven by improvements in healthcare services, higher living standards, and advances in medical treatments that have extended life expectancy. Cuvitru is used among older adults to manage primary immunodeficiency by delivering immunoglobulin replacement therapy that supports weakened immune systems. For instance, in January 2024, according to a report by the Population Reference Bureau, a US-based nonprofit organization, the population of Americans aged 65 and above is projected to grow from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Consequently, this age group’s share of the total U.S. population is expected to rise from 17% to 23% over the same period. Therefore, the growth of the aging population is supporting the expansion of the Cuvitru market.

The rise in healthcare spending is also expected to fuel the growth of the Cuvitru market going forward. Healthcare spending refers to the financial resources allocated by governments, organizations, and individuals toward healthcare services such as hospital care, medical treatments, pharmaceuticals, and preventive measures. Increasing healthcare expenditure is driven by factors including the growing burden of chronic diseases, expanding aging populations, advancements in medical technology, and the need to improve access to healthcare services. Higher healthcare spending supports the growth of the Cuvitru market by enabling broader access to advanced immunoglobulin therapies for patients with immune deficiencies. For example, in November 2024, according to the Health Foundation, a UK-based independent charity focused on healthcare, funding for NHS England is projected to increase from £171 billion ($216.1 billion) in the 2023/24 fiscal year to £192 billion ($242.64 billion) by 2025/26. Therefore, increasing healthcare spending is driving the growth of the Cuvitru market.

Major companies operating in the cuvitru market are Takeda Pharmaceutical Company Limited (Baxalta US Inc.)

Asia-Pacific was the largest region in the cuvitru market in 2025. The regions covered in the cuvitru market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cuvitru market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the cuvitru market by increasing costs of imported plasma-derived raw materials, fractionation equipment, sterile packaging, and cold-chain distribution systems. North America and Europe are most affected due to reliance on global plasma supply networks, while Asia-Pacific faces export-related cost pressures. These tariffs are raising therapy costs and supply management challenges. However, they are also encouraging regional plasma sourcing, domestic fractionation investments, and strengthened local immunoglobulin production capabilities.

The cuvitru market research report is one of a series of new reports that provides cuvitru market statistics, including cuvitru industry global market size, regional shares, competitors with a cuvitru market share, detailed cuvitru market segments, market trends and opportunities, and any further data you may need to thrive in the cuvitru industry. This cuvitru market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cuvitru is a medication that contains human immune globulin and is used to treat primary immunodeficiencies. It supports patients with weakened immune systems by providing essential antibodies that their bodies are unable to produce. The therapy helps restore antibody levels in individuals with conditions such as chronic granulomatous disease or severe combined immunodeficiency.

The primary indications for Cuvitru include common variable immunodeficiency (CVID), X-linked agammaglobulinemia, and severe combined immunodeficiency (SCID). Common variable immunodeficiency (CVID) is a primary immunodeficiency characterized by low antibody production and recurrent infections, and Cuvitru helps manage the condition by replenishing antibody levels through immunoglobulin replacement therapy. The product is distributed through hospital pharmacies, specialty pharmacies, and home healthcare providers, and is used in clinics, homecare settings, hospitals, and other healthcare environments.

The cuvitru market consists of sales of human immune globulin solution, infusion pumps, needles and syringes, and IV sets and tubing. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.